Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desvenlafaxine in Major Depressive Disorder
NCT00384033Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2006
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of desvenlafaxine in major depressive disorder (MDD) (4 arms), sponsored by Pfizer. Primary endpoint: Hamilton Rating Scale for Depression 17-item at 8 weeks. Started Sep 2006; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00384033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384033.